MedTrace Logo

Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.

NCT05142709 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1197

Last updated 2026-02-05

No results posted yet for this study

Summary

This study is a multi-center, non-interventional study. Clinicopathologic, treatment , outcome and efficacy data will be collected from medical records in metastatic esophageal squamous cell carcinoma (ESCC) patients.

Conditions

  • Metastatic Esophageal Squamous Cell Carcinoma

Interventions

DRUG

Anti-PD-1 Immune Checkpoint Inhibitors

used as 1st line treatment for metastatic ESCC.

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Lvhua Wang, M.D. · Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center

  • Kuaile Zhao, M.D. · Fudan University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-31
Primary Completion
2023-09-30
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05142709 on ClinicalTrials.gov